In Cohort 2, platelet counts were elevated, and fibrinogen levels reduced in the LC group compared with those of the placebo group
Career scientists at the FDA have continued to argue that there's insufficient evidence to suggest that many substances are safe or effective
Available from: Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, et al
The issue is summarised in the infographic below: The most significant issues described above can be summarised by the infographic below: In short, WADAs Section 4 Substance regime is fundamentally flawed, and could result in manifest injustices being committed against athletes
doi:10.1186/s12967-021-03195-5 99
Among the 25 studies included in the qualitative synthesis (16 in the meta-analysis), 15 focused specifically on serum cobalamin changes (reported by baseline and post-treatment means and standard deviations in pg/mL) and 10 reported homocysteine outcomes (means and standard deviations in mmol/L)